Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Public domain · source
Name	Chronic Obstructive Pulmonary Disease
Field	Pulmonology
Symptoms	Dyspnea, chronic cough, sputum production
Complications	Respiratory failure, pulmonary hypertension
Onset	Middle age
Duration	Long term
Causes	Tobacco smoke, air pollution
Risks	Smoking, occupational exposure
Diagnosis	Spirometry
Treatment	Smoking cessation, bronchodilators, oxygen therapy
Frequency	Common

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by airflow limitation that is not fully reversible, typically caused by long-term exposure to noxious particles or gases. It is a leading cause of morbidity and mortality worldwide, with prevalence influenced by patterns of tobacco use, industrialization, urbanization, and aging populations. Major public health actors and landmark initiatives have shaped awareness and policy responses to COPD in diverse regions.

Definition and epidemiology

COPD is defined by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to harmful particles or gases; diagnostic criteria are standardized by organizations such as the World Health Organization, Global Initiative for Chronic Obstructive Lung Disease, and national agencies including the National Institutes of Health and NHS (England). Global prevalence estimates are reported by institutions like the World Bank, United Nations, and regional bodies such as the European Commission and Pan American Health Organization; these estimates vary with smoking rates and occupational exposures recorded by entities like the International Labour Organization and World Trade Organization-influenced industrial patterns. Burden assessments appear in reports from the Centers for Disease Control and Prevention and national public health institutes, with demographic shifts noted in studies funded by the Bill & Melinda Gates Foundation and conducted at universities such as Harvard University and Imperial College London.

Causes and pathophysiology

Primary etiologic factors include long-term exposure to cigarette smoke, documented in research by institutions like the American Lung Association and regulatory responses from the Food and Drug Administration and European Medicines Agency. Other contributors include biomass fuel smoke in rural settings studied by the World Health Organization and occupational dusts and chemicals monitored by the International Labour Organization and national agencies such as the Occupational Safety and Health Administration. Pathophysiologic mechanisms involve chronic inflammation, protease–antiprotease imbalance described in literature from centers like the Mayo Clinic and Johns Hopkins Hospital, oxidative stress studied by laboratories at the Max Planck Society and Karolinska Institute, and remodeling of small airways linked to research at the National Heart, Lung, and Blood Institute. Genetic factors such as alpha-1 antitrypsin deficiency have been characterized by genetics groups at the University of Cambridge and clinical programs at the Cleveland Clinic.

Signs and symptoms

Typical manifestations include exertional dyspnea, chronic productive cough, wheeze, and recurrent lower respiratory tract infections; clinical descriptions appear in textbooks from publishers like Oxford University Press and Elsevier and training curricula used at institutions such as the Mayo Clinic and Royal College of Physicians. Exacerbations may present with increased dyspnea, sputum volume or purulence, and systemic features that prompt hospitalization in centers like Massachusetts General Hospital or St Thomas' Hospital. Comorbidities—cardiovascular disease, metabolic syndrome, osteoporosis—are managed in multidisciplinary clinics informed by guidelines from the American Thoracic Society and European Respiratory Society.

Diagnosis

Spirometry demonstrating a reduced ratio of forced expiratory volume in one second to forced vital capacity following bronchodilator administration is the diagnostic standard advocated by the Global Initiative for Chronic Obstructive Lung Disease and implemented in practice at hospitals such as Guy's and St Thomas' NHS Foundation Trust and research centers like Brigham and Women's Hospital. Imaging modalities including chest radiography and computed tomography are used for evaluation within radiology departments at institutions like the Royal College of Radiologists-affiliated centers and academic centers such as Stanford Health Care. Laboratory testing for alpha-1 antitrypsin deficiency is offered by reference laboratories and university hospitals including University College London Hospitals. Biomarkers and physiological assessments are topics of clinical trials registered with regulatory bodies like the European Medicines Agency and the U.S. Food and Drug Administration.

Management and treatment

Treatment principles—smoking cessation, pharmacotherapy, pulmonary rehabilitation, and oxygen therapy—are recommended by guideline-producing organizations such as the National Institute for Health and Care Excellence and the American Thoracic Society. Pharmacologic classes include bronchodilators and inhaled corticosteroids produced by pharmaceutical companies regulated by the European Medicines Agency and U.S. Food and Drug Administration; long-term oxygen therapy is prescribed following evidence from trials run at centers like Cleveland Clinic and Vanderbilt University Medical Center. Nonpharmacologic interventions include vaccination programs promoted by the World Health Organization and national health services such as the Centers for Disease Control and Prevention immunization schedules, pulmonary rehabilitation programs pioneered at institutions like the Royal Brompton Hospital, and surgical options—lung volume reduction surgery and transplantation—performed at specialty centers including Papworth Hospital and the U.S. Department of Veterans Affairs transplant programs. Health system responses integrate policy from bodies such as the World Health Organization, funding priorities from foundations like the Wellcome Trust, and clinical pathways developed at major hospitals.

Prevention and prognosis

Primary prevention focuses on tobacco control policies advanced by the World Health Organization Framework Convention on Tobacco Control, taxation strategies implemented by finance ministries in countries such as United Kingdom, Australia, and Canada, and clean energy initiatives promoted by the United Nations Environment Programme. Secondary prevention emphasizes early detection in primary care networks exemplified by programs in Scotland and New Zealand and occupational health regulations from the International Labour Organization. Prognosis correlates with disease severity, comorbidities, and access to care; long-term outcome data derive from cohort studies at centers like Karolinska Institute, Johns Hopkins University, and consortia funded by agencies such as the National Institutes of Health. Global efforts to reduce COPD burden engage multilateral organizations, national health systems, academic centers, and non-governmental funders.

Category:Respiratory diseases